Lundbeck: Alzheimer's agitation drug can make a real difference
R&D head Johan Luthman is pleased that Lundbeck’s Alzheimer’s agitation treatment candidate has gotten the FDA priority designation – ”agitation is one of the most troublesome aspects of the disease.”
by mikkel aabenhus hemmingsen, translated by daniel pedersen
It could make a real difference for patients and their relations if Lundbeck’s candidate, brexpiprazole, were approved to treat agitation associated with Alzheimer’s dementia (AAD), according to Johan Luthman, executive vice president for research and development at Lundbeck.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
